These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23838576)

  • 1. Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study.
    Hsu CH; Kang YK; Yang TS; Shun CT; Shao YY; Su WC; Sandoval-Tan J; Chiou TJ; Jin K; Hsu C; Cheng AL
    Oncology; 2013; 85(1):44-52. PubMed ID: 23838576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.
    Kaseb AO; Garrett-Mayer E; Morris JS; Xiao L; Lin E; Onicescu G; Hassan MM; Hassabo HM; Iwasaki M; Deaton FL; Abbruzzese JL; Thomas MB
    Oncology; 2012; 82(2):67-74. PubMed ID: 22327795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.
    Philip PA; Mahoney MR; Holen KD; Northfelt DW; Pitot HC; Picus J; Flynn PJ; Erlichman C
    Cancer; 2012 May; 118(9):2424-30. PubMed ID: 21953248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
    Cohen EE; Davis DW; Karrison TG; Seiwert TY; Wong SJ; Nattam S; Kozloff MF; Clark JI; Yan DH; Liu W; Pierce C; Dancey JE; Stenson K; Blair E; Dekker A; Vokes EE
    Lancet Oncol; 2009 Mar; 10(3):247-57. PubMed ID: 19201650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
    Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
    Chambers SK; Clouser MC; Baker AF; Roe DJ; Cui H; Brewer MA; Hatch KD; Gordon MS; Janicek MF; Isaacs JD; Gordon AN; Nagle RB; Wright HM; Cohen JL; Alberts DS
    Clin Cancer Res; 2010 Nov; 16(21):5320-8. PubMed ID: 21041183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
    Yau T; Wong H; Chan P; Yao TJ; Pang R; Cheung TT; Fan ST; Poon RT
    Invest New Drugs; 2012 Dec; 30(6):2384-90. PubMed ID: 22402942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
    Lubner SJ; Mahoney MR; Kolesar JL; Loconte NK; Kim GP; Pitot HC; Philip PA; Picus J; Yong WP; Horvath L; Van Hazel G; Erlichman CE; Holen KD
    J Clin Oncol; 2010 Jul; 28(21):3491-7. PubMed ID: 20530271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies.
    He L; Deng H; Lei J; Yi F; Li J; Fan X; Wei Y; Xu J; Zhang W
    BMC Cancer; 2019 Mar; 19(1):276. PubMed ID: 30922256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
    Hsu CH; Yang TS; Hsu C; Toh HC; Epstein RJ; Hsiao LT; Chen PJ; Lin ZZ; Chao TY; Cheng AL
    Br J Cancer; 2010 Mar; 102(6):981-6. PubMed ID: 20160718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
    Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
    J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
    Gautschi O; Mach N; Rothschild SI; Li Q; Stahel RA; Zippelius A; Cathomas R; Früh M; Betticher DC; Peters S; Rauch D; Feilchenfeldt J; Bubendorf L; Savic S; Jaggi R; Leibundgut EO; Largiadèr C; Brutsche M; Pilop C; Stalder L; Pless M; Ochsenbein AF;
    Clin Lung Cancer; 2015 Sep; 16(5):358-65. PubMed ID: 25843489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
    J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
    Thomas MB; Morris JS; Chadha R; Iwasaki M; Kaur H; Lin E; Kaseb A; Glover K; Davila M; Abbruzzese J
    J Clin Oncol; 2009 Feb; 27(6):843-50. PubMed ID: 19139433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
    Clarke JL; Molinaro AM; Phillips JJ; Butowski NA; Chang SM; Perry A; Costello JF; DeSilva AA; Rabbitt JE; Prados MD
    Neuro Oncol; 2014 Jul; 16(7):984-90. PubMed ID: 24637230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
    Johnsson A; Hagman H; Frödin JE; Berglund A; Keldsen N; Fernebro E; Sundberg J; De Pont Christensen R; Garm Spindler KL; Bergström D; Jakobsen A
    Ann Oncol; 2013 Sep; 24(9):2335-41. PubMed ID: 23788755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.
    Dingemans AC; de Langen AJ; van den Boogaart V; Marcus JT; Backes WH; Scholtens HTGM; van Tinteren H; Hoekstra OS; Pruim J; Brans B; Thunnissen FB; Smit EF; Groen HJM
    Ann Oncol; 2011 Mar; 22(3):559-566. PubMed ID: 20702788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.